MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today announced that the General Services
Administration (GSA) has awarded an unlimited 10-year reimbursement
contract to its Exosome Diagnostics laboratory, covering the ExoDx™
Prostate (EPI) test for men. The decision is effective today and
will be available to more than 140 government entities including
the VA Healthcare system, military branches such as Army, Navy, Air
Force, Marines, as well as the U.S. Senate and House of
Representatives and others. Now, approximately 9 million additional
men will have access to this non-invasive test for early detection
of prostate cancer. Details of the GSA award can be found on
the Company's website here.
The EPI test is a urine-based, genomic test that helps inform
the prostate biopsy decision. This liquid biopsy test recently
received FDA Breakthrough Designation and is included in the NCCN
guidelines for early detection in men for both initial and repeat
biopsy. It is performed by Exosome Diagnostics, a Bio-Techne brand,
in its CLIA, ISO, NY certified and CAP-accredited laboratory
located in Waltham, Massachusetts.
The EPI test is a risk assessment tool that assists physicians and
their patients with determining if a prostate biopsy is needed when
presented with an ambiguous PSA test result, thereby reducing
complications from unnecessary and invasive procedures.
According to Dr. Jeffrey A.
Jones, OCL Deputy Executive for Inpatient Services, Chief of
Urology for OCL/MEDVAMC, and Professor at Baylor College of Medicine, "Determining which
patients need prostate biopsy continues to be a challenge for
urologists and patients. We need better diagnostic tools, like a
prostate carcinoma exosome test, which has the potential to assist
in the physician-patient shared decision for prostate biopsy." He
continued, "Many patients could benefit from a non-invasive urine
test, such as the ExosomeDx Prostate test, to enhance the prostate
biopsy decision-making with more confidence. I look forward to such
diagnostic tools being available in the VA Healthcare system for
U.S. veterans."
"We are very pleased that GSA has joined a growing list of
payors and will now be reimbursing for the ExoDx Prostate Test,"
commented Chuck Kummeth, President
and Chief Executive Officer of Bio-Techne. "This coverage decision
enables almost 9 million additional men to make more informed
decisions on whether to proceed with an initial prostate biopsy.
The benefits of this test are increasingly resonating with both
patients and payors and we look forward to continuing to scale this
game-changing technology."
About Bio-Techne Corporation (NASDAQ: TECH)
ExosomeDx a Bio-Techne Brand
Contact: David Clair, Senior
Director, Business Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-technes-exosome-diagnostics-laboratory-announces-reimbursement-contract-with-general-services-administration-301025717.html
SOURCE Bio-Techne Corporation